Faricimab for Retinal Vein Occlusion: A Review of Current Evidence

AI Generated Summary*

A narrative review examines faricimab, a bispecific antibody blocking VEGF-A and angiopoietin-2, for macular edema secondary to retinal vein occlusion, arguing that single-target agents leave angiopoietin-2 driven endothelial destabilization and inflammation untreated. In phase III BALATON and COMINO trials (1,282 patients with branch or central occlusion, randomized to 6.0 mg faricimab or 2.0 mg aflibercept), letter gains were roughly 17 to 19, central subfield thickness fell more than 300 micrometres, leakage resolution favored faricimab; over half reached 12-week or longer intervals by week 68. One meta-analysis estimated about 2.4 fewer annual injections; another placed adverse event risk above bevacizumab and ranibizumab yet below aflibercept. Inflammation and vasculitis signals come from real-world AMD cohorts, and evidence past week 24 stays sparse.

*This summary was generated by AI and is published unedited. Oku does not alter these summaries. It may contain errors or omissions and is provided for general informational purposes only. Oku does not guarantee its accuracy, completeness, or reliability. For authoritative information, please refer to the original, peer-reviewed article.